The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolic, Angelo Maria Patti, Ali A. Rizvi Tags: Articles from the Incretin Hormones and Incretin-based Glucose-lowering Medications Special Issue, Edited by Michael Nauck, Manfredi Rizzo and Christos Mantzoros Source Type: research
More News: Biomedical Science | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Hormones | Incretin Therapy